Natriuretic peptides and heart failure in the patient with chronic kidney disease: a review of current evidence
- 1Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
- 2Cardiovascular Diseases Fellowship Program, Albert Einstein Medical Center, Pennsylvania, USA
- 3Department of Nephrology, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA
- 4Temple University Hospital, Department of Medicine, Philadelphia, Pennsylvania, USA
- Dr S Dhar, Department of Medicine, Drexel University College of Medicine, Abington Memorial Hospital, 1200 Old York Road, Abington, PA, USA; sunildhar{at}yahoo.com
- Received 1 August 2008
- Accepted 13 November 2008
Abstract
Natriuretic peptides such as brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) are commonly used in the diagnosis and evaluation of heart failure. However, their utility in patients with chronic kidney disease (CKD) is less clear as renal dysfunction itself can be associated with elevated concentrations of these biomarkers. Given the high prevalence of left ventricular hypertrophy and left ventricular systolic dysfunction in patients with CKD, diagnosis or exclusion of heart failure becomes important in this population. Most studies to date indicate that upward adjustment of diagnostic cut points preserves the usefulness of both BNP and NT-proBNP in the CKD patient, with similar clinical performance of each biomarker. We review the role of natriuretic peptide in heart failure in the setting of chronic renal disease.
Footnotes
-
Competing interests: None declared.









